<DOC>
	<DOCNO>NCT00329459</DOCNO>
	<brief_summary>This study design determine efficacy TREXIMA compare placebo treatment menstrual migraine .</brief_summary>
	<brief_title>Treximet ( Sumatriptan/Naproxen Sodium ) , Formerly Known TREXIMA , Menstrual Migraine Women With Dysmenorrhea</brief_title>
	<detailed_description>A randomized , double-blind , single migraine attack , placebo-controlled , parallel group , multicenter study evaluate efficacy tolerability TREXIMA* ( sumatriptan succinate/naproxen sodium ) tablets vs placebo administer mild pain phase menstrual migraine woman dysmenorrhea . ( TREXIMET formerly know TREXIMA )</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>At least 6 month history physician diagnose migraine typically experience 26 migraine attack per month . Typically experience moderate severe migraine pain precede mild pain phase . Differentiate mild migraine pain headache type . Women childbearing potential must adequate contraception . Pregnant and/or nursing mother . History cardiovascular disease . Uncontrolled hypertension . Basilar Hemiplegic migraine . History stroke transient ischemic attack ( TIA ) . History epilepsy treat antiepileptic within past 5 year . Impaired hepatic renal function . History gastrointestinal bleeding ulceration . Allergy hypersensitivity aspirin NSAID . Allergy hypersensitivity triptans . Participated investigational drug trial previous 4 week .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>menstrual migraine</keyword>
	<keyword>headache</keyword>
	<keyword>early intervention</keyword>
	<keyword>dysmenorrhea</keyword>
</DOC>